Nrx pharmaceuticals announces emergency use authorization of zyesami™ (aviptadil) in nation of georgia

Radnor, pa., july 27, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp) (nrx), a clinical stage, global biopharmaceutical company, today announced that the nation of georgia's prime minister and minister of health have issued an emergency use authorization for intravenous zyesami™ (aviptadil) for the treatment of critical covid-19.
NRXP Ratings Summary
NRXP Quant Ranking